Predicting response to neoadjuvant chemotherapy in breast cancer: Molecular imaging, systemic biomarkers and the cancer metabolome (Review)
Predicting response to neoadjuvant chemotherapy in breast cancer: Molecular imaging, systemic biomarkers and the cancer metabolome (Review)
复制标题
DOI：
10.3892/or_00000062
复制
发表时间：
2008-10-01
期刊：
影响因子：
4.2
通讯作者：
Eremin, Oleg
中科院分区：
文献类型：
--
作者：
Chuthapisith, Suebwong;Eremin, Jennifer M.;Eremin, Oleg
在患有大或局部晚期乳腺癌的女性中，在开始治疗之前或之后不久预测对新辅助化疗（NAC）的反应的能力不仅可以防止患者经历不必要的药物发病率，而且还可以降低与NAC的药物使用和资源利用相关的高成本。NAC后估计残留癌体积的能力与后续治疗手术选择具有临床相关性。各种方法，使用传统的组织病理学特征和成像方式来评估和预测对NAC的反应，还不能提供准确可靠的数据。新的生物分子成像，新的生物标志物和最近的癌症基因组和蛋白质组分析，引入临床实践，产生了初步的有希望的结果。我们描述和讨论这些分子特征和方法及其应用NAC在乳腺癌的管理。
The ability to predict the response to neoadjuvant chemotherapy (NAC) prior to or shortly after commencing treatment, in women with large or locally advanced breast cancers, would not only prevent patients from experiencing unnecessary drug morbidity but also reduce the high cost associated with drug usage and utilisation of resources with NAC. Ability to estimate residual cancer volume after NAC is of clinical relevance to subsequent therapeutic surgical options. Various approaches, using conventional histopathological characteristics and imaging modalities to evaluate and predict the response to NAC, have not been able to provide accurate and reliable data. Novel biomolecular imaging, new biomarkers and recent cancer genomic and proteomic profiling, introduced into clinical practice, have produced preliminary promising results. We describe and discuss these molecular characteristics and approaches and their applications to NAC in breast cancer management.